Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000831886
Ethics application status
Approved
Date submitted
7/07/2020
Date registered
29/06/2021
Date last updated
29/06/2021
Date data sharing statement initially provided
29/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Study to compare thermotherapy and intralesional drug injection for the treatment of patients with cutaneous leishmaniasis lesions in Syria.
Scientific title
Randomised controlled trial to determine the efficacy of thermotherapy in comparison with intralesional meglumine antimoniate to treat cutaneous leishmaniasis in an operational setting in Syria.
Secondary ID [1] 301576 0
PAR20002, Oxford University
Universal Trial Number (UTN)
U1111-1253-8297
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Cutaneous Leishmaniasis 317943 0
Condition category
Condition code
Skin 315977 315977 0 0
Other skin conditions
Infection 320201 320201 0 0
Other infectious diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The study will compare two treatments for cutaneous leishmaniasis: intralesional meglumine antimoniate (IL MA) and thermotherapy. IL MA is the standard treatment for CL in Syria, making thermotherapy the interventional treatment.

The device used in this study – ThermoMed Model 1.8 (Thermosurgery Technologies, Inc., Inc, Phoenix, AZ) - has received both Food and Drug Administration (FDA) and WHO approval for use in treatment of CL and is already in use by MENTOR in Syria. The handheld ThermoMed 1.8 device delivers controlled localised radio frequencies to small areas of tissue, which generates heat that is tolerable to healthy cells but intolerable for abnormal cells as well as parasites. The operating frequency is 6.78 MHZ +/- 15 KHZ and the output power 7 watts (+/-1).

The application follows several steps, which are laid out in a Standard Operating Procedure document, which is present at every treatment location. The application is as follows:
(a) After the applicator is properly placed on patient, depress handset button.
(b) Temperature will ramp up to the selected temperature. The ThermoMed will automatically terminate treatment after 4 seconds of the applicator is not making contact with the tissue being treated. Treatment will also be terminated if ramp-up (time to reach selected temperature) exceeds 45 seconds. If no treatment is administered for 15 seconds, the ThermoMed will automatically shut down.
(c) During ramp up to the temperature selected (50 degrees Celsius) the ThermoMed will produce a steady tone of increasing pitch to indicate the temperature sensed by the applicator thermocouple. The red light on the handset will be on. After the selected temperature (50 degrees Celsius) is reached:
- The audio output will change from a steady tone to a tone that beeps every 2 seconds
- The red light on the handset will change from steady to blinking
(e) After 30 seconds at the selected temperature:
- The ThermoMed will emit a 1 second tone burst.
- The red light on the handset will be on for the same interval as the tone.
- The first (30) indicator light on the ThermoMed unit will be turned on (red).

Standard treatment for CL with thermotherapy consists of 1 treatment session with application of the ThermoMed device for a duration of 30 seconds at a selected heat of 50 degrees Celsius to each treated area. Larger lesions may require more than 1 application during the same session to cover the entire lesion area. For smaller lesions 1 application of the ThermoMed device will suffice. For patients with several CL lesions, all lesions may be treated during the same treatment session. No further treatment sessions are required. Lesions on or directly adjacent to lips, eyes/eyelids, nose, ears, fingers/toes, close to close to carotid and jugular vessels in neck, the antecubital fossa region or on volar aspect of wrist joint should not be treated using this device. Implantable cardiac devices such as pacemakers and metallic implants such as metal plates in skull also exclude a patient from receiving this treatment.

All treatments with the thermotherapy device will take place in either a health facility or a mobile leishmaniasis clinic and all staff that administer the treatment must at least have a nursing degree.

As with the MA injections, adherence to the treatment will be monitored through the patient registration book, which is present at each MENTOR-supported health facility as well as all mobile leishmaniasis clinics and via the case report form (CRF) designed for this trial.
Intervention code [1] 317869 0
Treatment: Devices
Intervention code [2] 320163 0
Treatment: Drugs
Comparator / control treatment
The control treatment will be a course of intralesional Meglumine antimoniate (IL MA). MA is manufactured by Sanofi Aventis, France. It will be purchased and imported into Syria by MENTOR.

IL MA will be infiltrated around the CL lesions. The exact dose of MA will be determined at the clinician’s or nurse’s discretion, based on a thorough assessment of the lesion and depending on (a) the size of the lesion, (b) how elastic the skin is, and (c) how much of the drug leaks into the subcutaneous tissue layer. As a result, the volume of MA generally varies between 1 and 5mls. MENTOR will follow the WHO EMRO guidelines which state that each lesion should be injected twice per week for 3-4 weeks until complete cure is reached.

When injecting, the angle of the needle should be max 5-10 degrees to ensure injection into the dermal layer. 3-4 injection sites, 0.5 to 1cm outside the border of the lesion, should be chosen. These 3-4 injection sites should be at roughly equal distance from one another around the circumference of the lesion. Injection of the drug into the intradermal layer should cause blanching and slight swelling of the skin.

The drug will be injected by either a medical doctor or a qualified nurse at a MENTOR-supported health facility or a MENTOR mobile leishmaniasis clinic, which are visited by a Medical Officer at least once a week to provide on-the-job training, assess performance and assure that enough medical commodities are in stock.

Treatment adherence will be assessed via the patient registration book, which is present in all MENTOR-supported health facilities and mobile clinics, as well as the case report form (CRF) designed for this trial.
Control group
Active

Outcomes
Primary outcome [1] 324340 0
The primary outcome is a composite outcome and falls under the first study objective "To compare the efficacy of thermotherapy treatment to an IL course of MA for the treatment of cutaneous leishmaniasis at three months post treatment in Syria."

The primary study outcome is: "Complete re-epithelization for ulcerated lesions, and obvious flattening for non-ulcerated lesions measured at 3 months post treatment completion."

Photographs of the lesions pre- and post-treatment will be taken and sent to two dermatologists, who are blinded to treatment arm and determine the outcome (treatment success or failure) independently from each other. In case the two dermatologists disagree on the outcome, a third dermatologist, equally blinded, will determine the outcome.
Timepoint [1] 324340 0
3 months post treatment completion.
Secondary outcome [1] 384380 0
The secondary outcome is a composite secondary outcome and falls under the second objective of the trial "Determine leishmania species, genotypes & molecular markers of antimonial resistance."

The secondary outcome is: "PCR of kinetoplast DNA (species), sequence internal transcriber spacer 2 and cytochrome b genes (genotype), gene expression of e.g. aquaglyceroporin 1, multidrug resistance protein A."
Timepoint [1] 384380 0
Samples will be taken post-treatment completion to then determine the leishmania species, genotypes & molecular markers of antimonial resistance

Eligibility
Key inclusion criteria
All patients who present to the 5 selected static health facilities and mobile treatment clinics with Cutaneous Leishmaniasis lesions will be eligible for inclusion in this study if they meet all of the inclusion criteria and none of the exclusion criteria.

The inclusion criteria are as follows:
1. Participant with clinically diagnosed Old World Cutaneous Leishmaniasis < 4 cm in size
2. Participant is willing and able to give informed consent for participation in the study or
3. For children at least 5 years, a parent or guardian gives informed consent on their behalf
4. Participant agrees to follow the study processes and attend the follow-up appointment 3 months post treatment completion
Minimum age
5 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Pregnancy by history
2. Lactation
3. Lesions
*on or directly adjacent to lips, eyes/eyelids, nose
*nose
*ear
*fingers/toes
*close to carotid and jugular vessels in neck
*antecubital fossa region
*on volar aspect of wrist joint
4. Implantable cardiac devices such as pacemakers
5. Metallic implants such as metal plates in skull
6. Previous history of treatment to same lesion(s)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
For treatment allocation, the sequentially numbered, opaque sealed envelopes (SNOSE) method to randomly allocate treatment will be used. The preparation will follow the instructions given by Doig & Simpson (2005) in their paper “Randomization and allocation concealment: a practical guide for researchers.”, whereby a stack of SNOSE treatment allocation envelopes will be prepared and then a certain number of envelopes will be allotted to each study clinic.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Random number tables will be used in every study clinic. Each patient that enters the clinic for CL treatment and fulfils the requirements of entering the study will be allotted a number from the table, starting at the beginning of a column. If the number is even, he/she will be included in the trial sample and vice versa.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Phase 4
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
15/07/2021
Actual
Date of last participant enrolment
Anticipated
15/10/2021
Actual
Date of last data collection
Anticipated
15/02/2022
Actual
Sample size
Target
580
Accrual to date
Final
Recruitment outside Australia
Country [1] 22713 0
Syrian Arab Republic
State/province [1] 22713 0

Funding & Sponsors
Funding source category [1] 306002 0
Charities/Societies/Foundations
Name [1] 306002 0
The MENTOR Initiative
Country [1] 306002 0
United Kingdom
Primary sponsor type
Charities/Societies/Foundations
Name
The MENTOR Initiative
Address
4th Floor (South Suite),
Burns House, Harland Road,
Haywards Heath, RH16 1PG
Country
United Kingdom
Secondary sponsor category [1] 309043 0
None
Name [1] 309043 0
Address [1] 309043 0
Country [1] 309043 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 306237 0
Oxford Tropical Research Ethics Committee (OxTREC)
Ethics committee address [1] 306237 0
Ethics committee country [1] 306237 0
United Kingdom
Date submitted for ethics approval [1] 306237 0
05/06/2020
Approval date [1] 306237 0
18/02/2021
Ethics approval number [1] 306237 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 103206 0
Mr Hendrik Sauskojus
Address 103206 0
The MENTOR Initiative
Burns House, Harlands Road,
Haywards Heath, RH16 1PG
England, United Kingdom
Country 103206 0
United Kingdom
Phone 103206 0
+44 1444 412171
Fax 103206 0
Email 103206 0
[email protected]
Contact person for public queries
Name 103207 0
Hendrik Sauskojus
Address 103207 0
The MENTOR Initiative
Burns House, Harlands Road,
Haywards Heath, RH16 1PG
England, United Kingdom
Country 103207 0
United Kingdom
Phone 103207 0
+44 1444 412171
Fax 103207 0
Email 103207 0
[email protected]
Contact person for scientific queries
Name 103208 0
Hendrik Sauskojus
Address 103208 0
The MENTOR Initiative
Burns House, Harlands Road,
Haywards Heath, RH16 1PG
England, United Kingdom
Country 103208 0
United Kingdom
Phone 103208 0
+44 1444 412171
Fax 103208 0
Email 103208 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
Due to the sensitive Syrian context, we will not be able to share IPD data.


What supporting documents are/will be available?

Current supporting documents:
Doc. No.TypeCitationLinkEmailOther DetailsAttachment
8405Informed consent form  [email protected] 380037-(Uploaded-02-04-2021-02-19-22)-Study-related document.docx


Updated to:
Doc. No.TypeCitationLinkEmailOther DetailsAttachment
8405Informed consent form    380037-(Uploaded-02-04-2021-02-19-22)-Study-related document.docx
23857Statistical analysis plan   380037-(Uploaded-06-06-2024-20-36-58)-CL in Syria SAP Final 4-6-24.docx
23858Study protocol    380037-(Uploaded-06-06-2024-20-39-49)-Syria CL Study Protocol.docx

Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.